Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 58 clinical trials
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patient With Advanced Cancer

This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, PK, and PD profiles of AGEN2373 as a monotherapy and in combination with botensilimab (also known as AGEN1181), and to assess the maximum tolerated dose (MTD) in subjects with advanced solid tumors.

neutrophil count
anticoagulant therapy
measurable disease
bladder cancer, squamous cell carcinoma
  • 24 Jul, 2022
  • 8 locations
Pembrolizumab + Poly-ICLC in MRP Colon Cancer

The main purpose of this study is to determine the dose of poly-ICLC that is safe and tolerable when it is combined with pembrolizumab in patients with colon cancer. This study will also evaluate how the combination of pembrolizumab and poly-ICLC activates the immune system in the patient's blood and …

measurable disease
  • 01 Mar, 2022
  • 1 location
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Metastatic Solid Tumors

This study has 2 phases. The main aims of Phase 1b are: to check for side effects from modakafusp alfa in adults with locally advanced or metastatic solid tumors. to learn how much modakafusp alfa adults can receive without getting any major side effects from it. The main aims of …

solid tumour
neck cancer
malignant melanoma of skin
  • 01 Jul, 2022
  • 12 locations
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (ANIMATE)

This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory classical Hodgkin lymphoma patients not achieving a complete metabolic response (CMR) on FDG-PET-CT scan after …

refractory hodgkin lymphoma
pd-1 inhibitor
  • 12 May, 2022
  • 9 locations
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) Group B: Trastuzumab + Vinorelbine + Avelumab Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)

measurable disease
primary tumor
  • 21 Jul, 2022
  • 16 locations
Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (GlitIpNi)

Phase I clinical trial on intra-tumoral ipilimumab plus intravenous nivolumab following the resection of recurrent glioblastoma. The aim of this clinical trial is to exploit the potential synergy of combined intra-tumoral CTLA-4 and systemic PD-1 blockade while minimizing the risk for increased immune-related toxicity by intratumoral administration of the CTLA-blocking …

neutrophil count
recurrent glioblastoma
blood transfusion
  • 25 Feb, 2022
  • 1 location
T-cell Therapy in Combination With Nivolumab Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Although immunotherapy has revolutionized the treatment of many cancers, ovarian cancer patients have not yet benefitted from the advances. In two consecutive pilot trials at National Center for Cancer Immune Therapy (CCIT-DK), is has been have shown that adoptive cell therapy (ACT) with TILs for patients with advanced ovarian cancer …

  • 16 May, 2021
  • 1 location
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of patients with bone metastases cancer with unknown primary, and provide a better treatment plan for these patients. Primary outcome: …

Accepts healthy volunteers
  • 23 Mar, 2022
  • 1 location
Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

This study is designed with open-label and randomized parallel group to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an add-on treatment for primary glioblastoma multiforme

neutrophil count
residual tumor
brain tumor
tumour resection
  • 11 Apr, 2022
  • 3 locations
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously threatens the lives and health of the people. The investigators establish multi-center, retrospective research methods, collecting …

  • 28 Jun, 2022
  • 1 location